louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01787643: Standing Behavior After Installation of Height-Adjustable Desks
Official title: Adoption of Standing Behavior After Installation of Height-Adjustable Desks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Office Workers
Sitting Occupations
Keywords: height-adjustable desk
office workers
sitting occupations
energy expenditure
BMI
Weight
Lower fat diet
Lead sponsor: USDA Grand Forks Human Nutrition Research Center
Sponsor class: FED
First posted: 2013-02-08
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this research study is to determine whether height-adjustable desks change sitting and standing time at work and away from work, engery expenditure, dietary intake, and body composition. Intermittent peroids of standing made possible by height-adjustable desks may help to impart long-term health benefits.


Eligibility criteria: Inclusion Criteria:

* Being one of the 18 scientists and support staff who have sedentary jobs
* Voluntarily make the choice to replace their current fixed-height sitting desk for a sit-to-stand height-adjustable desk
* Consents to study conditions

Exclusion Criteria:

* Cannot stand for any type of health of orthopedic reasons
* Do not work fulltime
* Pregnant at baseline or become pregnant during the study

Primary outcomes:
measure: Workplace sitting time to be reduced
timeFrame: 12 months
Secondary outcomes:
measure: Total sitting time will be reduced
timeFrame: 12 months
measure: Energy expenditure will increase
timeFrame: 12 months
measure: Health behavior change of consuming a lower fat diet
timeFrame: 12 months
measure: Body weight, BMI, and fat mass reduction
timeFrame: 6 months
measure: Changes in musculoskeletal symptoms
timeFrame: 12 months
Other outcomes:
Locations:
city: Grand Forks
country: United States
facility: USDA Grand Forks Human Nutrition Research Center
state: North Dakota
Study officials:
affiliation: USDA Grand Forks Human Nutrition Research Center
name: James Roemmich, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Roemmich JN. Height-Adjustable Desks: Energy Expenditure, Liking, and Preference of Sitting and Standing. J Phys Act Health. 2016 Oct;13(10):1094-1099. doi: 10.1123/jpah.2015-0397. Epub 2016 Aug 16.
Clinical trial NCT00712543: A Preference Study Comparing Kristalose® and Liquid Lactulose
Official title: A Preference Study Comparing Kristalose® and Liquid Lactulose in the Treatment of Constipation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Constipation
Keywords: constipation
laxative
lactulose
Kristalose®
Lead sponsor: Cumberland Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2008-07-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study will evaluate whether patients have an overall preference for Kristalose® or liquid lactulose based on taste, consistency, and portability.

Detailed description: This study will evaluate whether patients have an overall preference for Kristalose® or liquid lactulose based on taste, consistency, and portability.

Eligibility criteria: Inclusion Criteria:

* Patients with recently diagnosed chronic constipation requiring treatment.

Exclusion Criteria:

* Patients with galactosemia (galactose-sensitive diet).
* Patients less than 18 years of age.
* Patients currently on lactulose therapy.
* Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board \[IRB\]) and agree to abide by the study restrictions.

Primary outcomes:
measure: Patient Preference in Terms of Overall Preference and Preference of Taste, Consistency, and Portability.
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: Arya Gastroenterology Associates
state: New York
city: Raleigh
country: United States
facility: Wake Research Associates
state: North Carolina
city: Cleveland
country: United States
facility: Rapid Medical Research
state: Ohio
Study officials:
References:
Clinical trial NCT00395343: Sitagliptin Added-on to Insulin Study (0431-051)
Official title: A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2006-11-02
Enrollment: 641
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.


Eligibility criteria: Inclusion Criteria:

* Patient has type 2 diabetes mellitus
* Patient is poorly controlled while on insulin or insulin and metformin

Exclusion Criteria:

* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis
* Patient is taking oral antidiabetic agents other than metformin during the past 3 months
* Patient is currently on treatment with daily use of pre-prandial short-acting or rapid-acting insulin

Primary outcomes:
measure: Change From Baseline in A1C at Week 24
timeFrame: Baseline and Week 24
Secondary outcomes:
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
timeFrame: Baseline and Week 24
measure: Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24
timeFrame: Baseline and Week 24
measure: Percent Change From Baseline in Index of Static Beta-Cell Sensitivity to Glucose at Week 24
timeFrame: Baseline and Week 24
measure: Percent of Patients With A1C < 7.0% at Week 24
timeFrame: 24 Weeks
measure: Percent of Patients With A1C < 6.5% at Week 24
timeFrame: Week 24
Other outcomes:
measure: Change From Baseline in A1C at Week 24
timeFrame: Baseline and Week 24
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010 Feb;12(2):167-77. doi: 10.1111/j.1463-1326.2009.01173.x.
Clinical trial NCT00591643: Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)
Official title: Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Adrenal Tumors
Adrenal Malignancies
Abnormal Hormonal Secretions
Electrolytes Abnormalities
Keywords: Adrenal tumors
Adrenal malignancies
abnormal hormonal secretions
electrolytes abnormalities
Imaging
Scanning
tumor localization
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2008-01-11
Enrollment: 93
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol. This labeled material had been used as an investigative diagnostic tool for imaging adrenal glands for many years with success in our hands. This is a diagnostic procedure. CT, MRI and Ultrasound can determine the size and presence or absence of tumor but cannot assess the function of the adrenal glands. To determine hormone concentrations from blood samples would involve more invasive catherization.

Detailed description: To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.

Eligibility criteria: Inclusion Criteria:

* Patient with clinical and laboratory suspicions of hypersecretion of adrenal cortical hormones

Exclusion Criteria:

* n/a

Primary outcomes:
measure: To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Neeta Pandit-Taskar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06660043: Influence of Bodily Practices on the Quality of Life of Women With Endometriosis
Official title: Influence of Bodily Practices on the Quality of Life of Women
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Endometriosis
Lead sponsor: Fondation Hôpital Saint-Joseph
Sponsor class: OTHER
First posted: 2024-10-26
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This research focuses on understanding how physical activity can improve the quality of life for women with endometriosis by enhancing their self-perception, particularly regarding their physical abilities and appearance. The study is based on the idea that improving internal perceptions can lead to better overall well-being for these women. Previous studies, suggest that physical self-perception plays a crucial role in shaping an individual's quality of life. There is also evidence supporting a reciprocal relationship between physical self-concept and participation in physical activity

In this context, the research aims to explore how physical activity could positively influence the self-concept of women suffering from endometriosis, which in turn could enhance their quality of life. By focusing on improving both physical abilities and body image through regular exercise, this study seeks to offer insights into potential therapeutic approaches for managing the physical and psychological impacts of endometriosis.


Eligibility criteria: Inclusion Criteria:

* Menstruating women aged 18 to 55;
* proven diagnosis of endometriosis (pelvic ultrasound or MRI)
* Having endometriosis-related pain of a level higher than 3 on the VAS scale and/or chronic incapacitating symptoms related to endometriosis;
* Patient without treatment or with stable endometriosis treatment (pill and/or ATG) who has not undergone treatment during the last 6 months;
* Patient affiliated to a health insurance scheme;
* French-speaking patient;
* Patient having given free, informed and express oral consent.

Exclusion Criteria:

* Any patient whose endometriosis treatment has been modified for less than 6 months;
* Having endometriosis-related pain greater than or equal to 8 on the VAS scale;
* Cardiovascular risks related to physical training;
* Inability to perform proposed exercises;
* Patient under guardianship;
* Patient deprived of liberty;

Primary outcomes:
measure: Evaluation of quality of life
timeFrame: 6months
Secondary outcomes:
Other outcomes:
Locations:
city: Chevry-Cossigny
country: France
facility: Physical Therapy Studio
city: Paris
country: France
facility: Hôpital Saint Joseph
Study officials:
affiliation: Fondation Hôpital Saint-Joseph
name: Frederique PERROTTE
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02480543: Different Routes of Misoprostol Prior to First Trimester Surgical Abortion
Official title: Different Routes of Misoprostol for Same-day Cervical Preparation Prior to First Trimester Surgical Abortion: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Abortion, Induced
Lead sponsor: Wolfson Medical Center
Sponsor class: OTHER_GOV
First posted: 2015-06-24
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A randomized clinical trial to assess the effectiveness of same-day cervical preparation with oral, buccal or vaginal Misoprostol, given 2-4 hours prior first trimester curettage.


Eligibility criteria: Inclusion Criteria:

* Patients admitted for elective first trimester abortion (termination of pregnancy/ missed abortion) at Wolfson Medical Center, gestational age \<13+0 weeks
* Written consent supplied

Exclusion Criteria:

* Contraindications to prostaglandin treatment (severe asthma, glaucoma, severe cardiac disease, renal failure)
* Prostaglandin allergy
* Genital infection
* Space-occupying lesion in the endocervical canal
* Prior cervical surgery

Primary outcomes:
measure: Preoperative cervical width in centimeters
timeFrame: intraoperative
Secondary outcomes:
measure: Time required to achieve cervical dilatation
timeFrame: intraoperative
measure: Ease of cervical dilatation
timeFrame: intraoperative
measure: Patient preference
timeFrame: baseline
measure: Adverse effects of medication
timeFrame: baseline
measure: Surgical complications
timeFrame: intraoperative
Other outcomes:
Locations:
city: Holon
country: Israel
facility: Edith Wolfson Medical Center
Study officials:
affiliation: Edith Wolfson Medical Center
name: Hadas Ganer Herman, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ghosh J, Papadopoulou A, Devall AJ, Jeffery HC, Beeson LE, Do V, Price MJ, Tobias A, Tuncalp O, Lavelanet A, Gulmezoglu AM, Coomarasamy A, Gallos ID. Methods for managing miscarriage: a network meta-analysis. Cochrane Database Syst Rev. 2021 Jun 1;6(6):CD012602. doi: 10.1002/14651858.CD012602.pub2.
Clinical trial NCT03121443: Patient Positions and Perfusion Index
Official title: The Association Between Surgical Patient Positions and Perfusion Index
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Perfusion
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2017-04-20
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Volunteers American society of anesthesiologists score of 1

Brief summary: The association between patient positions including supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position and perfusion index.

Detailed description: Participants are taken to the recovery room and they will wait 15 minutes until measurements. After monitoring the perfusion index using the right ring finger, first the participant will be taken to supine position. The perfusion index value will be obtained after three minutes of measurement. Second, the position will change to 45 degrees back up sitting position and the measurement will be repeated. Then the participant will be taken to Trendelenburg position, reverse Trendelenburg position, prone, 45 degrees legs lifted supine position respectively, and same measurement will perform.

Eligibility criteria: Inclusion Criteria:

* American society of anesthesiologists score of 1

Exclusion Criteria:

* any kind of disease

Primary outcomes:
measure: Perfusion index
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Gaziosmanpasa University
Study officials:
affiliation: Assistan professor
name: Hakan Tapar
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03779243: Treatment for Sleep Disturbance in Orthopaedic Trauma Patients
Official title: Melatonin Treatment for Sleep Disturbance in Orthopaedic Trauma Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Disturbance
Trauma
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2018-12-19
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to test the efficacy of sleep treatment in human patients following traumatic injury. Specifically, the study will determine if treatment consisting of melatonin and education related to sleep habits are effective in treating sleep disturbance and improving sleep quality in Orthopaedic trauma patients. We hope to learn if melatonin and sleep education effectively improve sleep following traumatic injury, and improve outcomes.


Eligibility criteria: Inclusion Criteria:

* New patients visiting the Orthopaedic Trauma Clinic or undergoing orthopaedic surgery in Stanford Hospital following traumatic injury. Accidental traumatic fracture injuries that are operative and non-operative. Must be able to swallow tablets.

Exclusion Criteria:

* Documented head trauma. Cognitive impairments. Minors. Previously diagnosed sleep disorders. Sleep apnea. Enrolled in another study. Women who are pregnant or may become pregnant or are nursing. Hypertension. Diabetes. Endocrine, autoimmune, depressive, bleeding or seizure disorders.

Primary outcomes:
measure: Mean Change in Pittsburgh Sleep Quality Index Score
timeFrame: Baseline, week 6, and week 12
Secondary outcomes:
measure: 36-Item Short Form Survey (SF-36) to measure quality of life
timeFrame: Baseline, week 6, and week 12
measure: Mean Change from Baseline in Pain Scores on the Visual Analog Scale (VAS)
timeFrame: Baseline, week 6, and week 12
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford
state: California
Study officials:
affiliation: Stanford Department of Orthopaedic Surgery
name: Michael J Gardner, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Swann MC, Batty M, Hu G, Mitchell T, Box H, Starr A. Sleep Disturbance in Orthopaedic Trauma Patients. J Orthop Trauma. 2018 Oct;32(10):500-504. doi: 10.1097/BOT.0000000000001276.
Clinical trial NCT01283243: Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients
Official title: Prospective Study for Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients Without Abnormal Liver Function and Chronic Liver Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: HIV Infection
Keywords: ARFI Imaging
Normal values
HIV infection
Lead sponsor: Yonsei University
Sponsor class: OTHER
Collaborators: name: Severance Hospital
First posted: 2011-01-25
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: HIV patients without abnormal liver function and chronic liver disease

Brief summary: This is a prospective cohort single center study for assessment of normal value of acoustic radiation force impulse elastography and fibroscan in HIV patients without abnormal liver function and chronic liver disease.

Detailed description: HIV positive patients who have liver dysfunction have shown to be correlated with high mortality and morbidity. To date, ARFI elastography has been known to correlate with the degree of liver fibrosis in chronic liver disease. However, ARFI velocity has not yet been reported in HIV patients. The aim of this study was to identify the normal range of ARFI velocity and liver stiffness value by recruiting HIV patients without abnormal liver function and chronic liver disease.

Eligibility criteria: Inclusion Criteria:

* Age \> 20 years
* HIV positive patients
* The patients who is willing and able to provide written informed consent to participate in this study

Exclusion Criteria:

* Co-infected with HIV and HBV or HCV
* History of any other forms of liver disease
* Any gross abnormality on the imaging finding including MRI and CT
* Any laboratory abnormalities regarding liver condition (Platelet count \< 150 x 103/ul, Fasting glucose \> 110 mg/dl, AST \> 40 IU/L, ALT\> 40 IU/L, Albumin \< 3.3 g/dl, Total bilirubin \> 1.2 mg/dl, GGT\> 54 IU/L, ALP \> 115 IU/L , Ferritin \> 322 ng/ml)

Primary outcomes:
measure: Evaluation of ARFI velocity in HIV patients
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
affiliation: Yonsei University Colleage of Medicine
name: Kwang-Hyub Han, MD
role: STUDY_CHAIR
affiliation: Yonsei University Colleage of Medicine
name: Seung Up Kim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00394290: Down Syndrome and Continuous Positive Pressure Therapy
Official title: Follow-up of the Therapeutic Coverage by Continuous Positive Pressure of the Obstructive Sleep Apnea Syndrome for Down Syndrome Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Down Syndrome
Obstructive Sleep Apnea Syndrome
Keywords: Down Syndrome
Obstructive Sleep Apnea Syndrome
Continuous Positive Pressure
Hypersomnia
Lead sponsor: Institut Jerome Lejeune
Sponsor class: OTHER
Collaborators: name: Fondation Jérôme Lejeune
First posted: 2006-11-01
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and tolerability of Continuous Positive Pressure for SAOS in Down Syndrome patients.


Eligibility criteria: Inclusion Criteria:

* Down Syndrome patients with an Obstructive Sleep Apnea Syndrome
* more than 18 years old

Exclusion Criteria:

* predictable non-compliance of device
* non-compensated cardiopathy
* non-stable thyroxin treatment
* non-stable diabetes

Primary outcomes:
measure: Scores on psychometrical and dementia scales after a 3-month treatment period (and if possible, after 12 months)
timeFrame: 0 and 3 months
Secondary outcomes:
measure: Tolerability
timeFrame: 0, 3 and 12 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut Jerome Lejeune
Study officials:
affiliation: Institut Jerome Lejeune
name: Martine Conte, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Institut Jerome Lejeune
name: Franck STURTZ, M.D.
role: STUDY_DIRECTOR
References:
citation: Resta O, Barbaro MP, Giliberti T, Caratozzolo G, Cagnazzo MG, Scarpelli F, Nocerino MC. Sleep related breathing disorders in adults with Down syndrome. Downs Syndr Res Pract. 2003 Aug;8(3):115-9. doi: 10.3104/reports.138.